RedHill Biopharma ( (RDHL) ) just unveiled an update.
On March 12, 2025, RedHill Biopharma announced plans to advance its late-stage Crohn’s disease program with a Phase 2 study of RHB-204, following statistically significant positive results from the Phase 3 study of RHB-104. The new study will focus on MAP-positive patients, aiming to demonstrate improved efficacy and safety with a reduced pill burden and expedited timeframe, potentially offering a paradigm-shifting therapeutic approach in the expanding multibillion-dollar Crohn’s disease market.
More about RedHill Biopharma
RedHill Biopharma Ltd. is a specialty biopharmaceutical company focused on developing innovative therapies for gastrointestinal diseases. The company is advancing its late-stage program for Crohn’s disease with a focus on Mycobacterium avium subspecies paratuberculosis-positive (MAP+) patients.
YTD Price Performance: -56.41%
Average Trading Volume: 57,888
Technical Sentiment Consensus Rating: Buy
Current Market Cap: $3.56M
Find detailed analytics on RDHL stock on TipRanks’ Stock Analysis page.